Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Friday
Sep 03rd
Home arrow Farmavita.Net Journal arrow Business Reports
Farmavita.Net - Business Reports
Print E-mail
Market Report

datamonitor_logo.gif

Cystic Fibrosis - A pipeline full of hope

With cystic fibrosis patients still dying prematurely and only two products currently approved for the treatment of this disease, the market is wide open for new entrants. Not only will novel symptomatic treatments and re-formulations lead to improved treatment paradigms, truly disease-modifying compounds are in late-stage development and will significantly change the market.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Bone building drugs become the heart of the pipeline

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 2009. Nonetheless, several promising pipeline drugs will help the market resume growth.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Market players maximize revenue growth before the next challenging phase

Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005/09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drugs. The NGF class has potential to be first of an entirely new type of painkiller to enter the sector in decades. Nevertheless, high expectations need to be tempered once the long term side effects, safety and pharmacoeconomics have been established.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Fibromyalgia - Regulatory caution threatens EU market expansion

Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than double in value from 2008 to total $2.5 billion by 2018 across the seven major regions.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies. Collectively, the nine drugs in late-phase development are forecast to achieve $2,780m in sales by 2018.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies

No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts. However, with one product in pre-registration in the US, the prospect of the first marketed therapeutic cancer vaccine in the seven major markets is now closer to reality.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Hepatitis C - High unmet need drives rapid innovation

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey

China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 19 - 27 of 366
Advertisement
 

Featured Partners

2010_pharmaci_banner_150x150.gif
jfbals88_banner_150x150_2.gif
bals89_150x150.gif
150x150_g-2.gif 
  dbls02_150x150banner.gif
150x150.gif
evolution_2010_150x150.gif
150x150_chronic10_master.gif
150x150_riskshna10_master.gif
dbls03_150x150_anim.gif
banner150_pm2010.gif
bals91_150x150_anim.gif

Login to Farmavita.Net

membership is FREE

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 77 guests online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

bals90_150x150_anim.gif  

Reports

rbhc0264_privatehealthcare.gif 

Events

  chc197_150x150.gif

REPORTS

farmavita_research-store.gif